Barclays initiated coverage of Dentsply Sirona (XRAY) with an Underweight rating and $12 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XRAY:
- DENTSPLY SIRONA Appoints Interim CFO Michael Pomeroy
- Dentsply Sirona price target lowered to $14 from $18 at Barrington
- Dentsply Sirona price target lowered to $12 from $14 at Morgan Stanley
- Dentsply Sirona price target lowered to $13 from $16 at Mizuho
- Dentsply Sirona price target lowered to $12 from $14 at JPMorgan